Tempus AI shares are trading higher Monday morning. The company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD device.

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 5% on Monday after the company announced it received 510 (k) clearance from the U.S. Food and Drug Administration for its RNA-based Tempus xR ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510 (k) clearance from the U.S. Food and ...

SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its ...

The company says a single node is capable of processing approximately 22,000 genomes annually, triple the amount of earlier releases.

Modern agriculture faces mounting challenges from climate change, soil degradation, and rising biotic and abiotic stresses, ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Qiagen N.V. is one of ...

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a method that can measure the kinetic efficiency of an enzyme against more than 200,000 potential peptide ...

The single cell analysis market is estimated to reach $13.62 billion by 2031, growing at a CAGR of 17.8% from 2022 to 2031.

The Business Research Company’s Somatic Genetic Testing Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 ...

The T7+ integrates MGI's proprietary DNBSEQ™ technology with next-generation fluidics, optics, and bioinformatics, creating a platform that is faster, smarter, and more versatile than ever before. The ...

Next-generation sequencing enhances a biologics manufacturer's ability to detect and identify unknown or unexpected contaminants.